SISVEL
7.1.2016 17:46:21 CET | Business Wire | Press release
Sisvel, a global licensing company that has been dedicated to patent licensing since its foundation in 1982, has announced today that it is going beyond traditional patent licensing in how it acquires and monetizes patent portfolios and partners with IP players.
Sisvel is now offering its IP commercialization platform to anyone who wishes to gain greater value from Intellectual Property. This platform allows both IP Buyers and Sellers to use Sisvel’s proven network of partners, expertise in licensing and technical analysis – something no other entity now offers.
“IP buyers and sellers are in dire need to be directed by a competent player in the marketplace,” said Karel van Lelyveld, CEO of the Sisvel Group. “Sisvel has been active in this market for more than 30 years and we know what it takes to find the proverbial needle in a haystack. With our new IP Commercialization Platform we now provide easy and immediate access to buyers and sellers who want to transact assets. Our platform provides the simplicity and transparency needed to take back the market for those who develop innovative technologies and those who are seeking to get IP protection for innovative solutions”.
IP Commercialization Platform Features:
- Match for IP: Sisvel’s IP platform bridges buyer and seller requests and helps both parties achieve efficient solutions.
- Marketing IP Correctly: Sisvel’s team can help a company structure and optimize its Intellectual Property (IP) portfolio as well as identify the right assets to monetize.
- Finding the Proverbial Needle in a Haystack: Companies from around the world can now find specific IP assets in technical areas of interest, from selected sellers and pre-qualified portfolio opportunities.
“With Sisvel in the mix, there is no need to run around to ten or twenty different firms trying to buy access to the technologies you may need,” said Chuck Hausman, Vice President of Sisvel US.
Sisvel will formally unveil its new worldwide IP commercialization platform at CES 2016 with an announcement during a private reception on Thursday, January 7 from 4-6 p.m in the LVCC South Hall, Booth #1-20306. Sisvel’s management team will be available at the event to discuss the new platform’s benefits.
RSVP and further information:
Veronica Pugi veronica.pugi@sisvel.com
Sue
Ellen Schaming sschaming@hoogcomm.com
About Sisvel
Started in 1982 when Sisvel S.p.A. was founded
in Italy, the Sisvel Group has become a world leader in managing
intellectual property and maximizing the value of patent rights. The
Sisvel Group is global in scope and reach, with subsidiaries in Italy
(Sisvel and Sisvel Technology in None Torinese), the United States
(Sisvel US and Audio MPEG in Metropolitan Washington, DC), China (Sisvel
Hong Kong), Japan (Sisvel Japan in Tokyo), Germany (Sisvel Germany in
Stuttgart), Luxembourg (Sisvel International), and the United Kingdom
(Sisvel UK), with over one hundred professionals worldwide with
engineers, legal, and licensing expertise. Sisvel has a long history of
managing successful patent portfolios including those related to the
audio compression standards known as MP3 and MPEG Audio, and widespread
technologies such as OSD (On Screen Display), ATSS (Automatic Tuning &
Sorting System), and WSS (Wide Screen Signalling - for automatic
switching of television image formats). Sisvel currently operates patent
pools and joint licensing programs for the DVB-T, DVB-T2, LTE/LTE-A and
Wi-Fi standards, together with its Sisvel Wireless licensing program and
is in the process of creating a new licensing program for DVB-C2.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005959/en/
Contact:
Media Contact
Sisvel Group
Veronica Pugi, Tel: +
39 011 990 4114
Senior Communications Officer
veronica.pugi@sisvel.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
